Author: Ken Dropiewski

Positive 12-Month Data on BioCardia’s Investigational CardiAMP Cell Therapy System for Heart Failure Presented at American Heart Association Scientific Sessions 2018

CHICAGO & SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced positive 12 month data for the roll-in cohort of its pivotal CardiAMP™ Heart Failure Trial studying the investigational CardiAMP Cell Therapy System in adult patients experiencing heart failure following a […]

Cardurion Pharmaceuticals Presents Preclinical Data for CRD-733 at the American Heart Association Scientific Sessions and Announces Initiation of Phase 1b Study in Patients with Heart Failure

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced preclinical results from its study of CRD-733, the company’s novel Phosphodiesterase-9 enzyme (PDE-9) inhibitor, in a poster presentation at the American Heart Association (AHA) Scientific Sessions in […]

New Prevencio Study Using AI Demonstrates Novel Blood Test Accurately Predicts Acute Kidney Injury (AKI) Risk

KIRKLAND, Wash.–(BUSINESS WIRE)–Prevencio, Inc. today announces data demonstrating high accuracy for its multiple-protein HART AKITM test. Researchers believe these important findings, presented November 10 at the 2018 American Heart Association (AHA) Scientific Sessions in Chicago, will lead to more accurate prediction of AKI risk. This could alter patient management and reduce […]

Shifa Biomedical Corporation Presents Preclinical Data on P-21, a Novel Orally Active PSCK9 Antagonist, at the American Heart Association (AHA) Meeting, Scientific Sessions 2018

CHICAGO, Nov. 12, 2018 (GLOBE NEWSWIRE) — Shifa Biomedical Corporation (Shifa), a drug discovery biopharmaceutical company focused on developing novel agents to treat cardiovascular disease and hypercholesteremia, today announced exciting preclinical data involving the company’s pre-clinical candidate, P-21, which interferes with the interaction between PCSK9 and the LDL receptor (LDLR). […]

MyoKardia Presents Preclinical Evidence of Mavacamten’s Novel Effect on Diastolic Compliance at the 2018 American Heart Association Scientific Sessions

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2018 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, presented preclinical data at the American Heart Association (AHA) Scientific Sessions 2018 that demonstrated that targeting the heart’s motor protein, myosin, improved ventricular […]

GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions

WESTMINSTER, Colo., Nov. 12, 2018 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that data from the Atrial Fibrillation Burden (AFB) substudy of the Phase 2B GENETIC-AF clinical trial were presented November 11, 2018 in a poster session at […]

BioSig Technologies to Ring NASDAQ Opening Bell on November 13, 2018

Santa Monica, CA, Nov. 12, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, announced today its Founder, Chairman & CEO […]

Philips announces first U.S. patient enrolled in ILLUMENATE study of Stellarex 0.014 Drug-Coated Balloon for below-the-knee peripheral artery disease

AMSTERDAM, Nov. 12, 2018 /PRNewswire/ — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced enrollment of the first U.S. patient in the Stellarex ILLUMENATE Below-the-Knee (BTK) Investigational Device Exemption (IDE) study, led by principal investigators Dr. Bill Gray and Dr. Mahmood K. Razavi. This unique global, prospective, randomized, multi-center trial is designed […]

AliveCor’s Mobile ECG Technology Could Enable More Rapid Diagnosis and Treatment of Heart Attacks

MOUNTAIN VIEW, Calif., Nov. 12, 2018 /PRNewswire/ — AliveCor, the leader in FDA-cleared personal electrocardiogram (ECG) technology, has announced that a research version of its mobile technology can identify ST-elevation myocardial infarction (STEMI), the most severe form of heart attack. The findings of the ST LEUIS International Multicenter Study, to be announced at […]